Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

2(40.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05844644Phase 2Recruiting

The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes

Role: lead

NCT05844631Phase 2Completed

The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults

Role: lead

NCT04082390Not ApplicableUnknown

Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance

Role: lead

NCT03842501Phase 3Completed

Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity

Role: lead

NCT03478202Not ApplicableCompleted

GOLO Open-Label Pilot 1

Role: lead

All 5 trials loaded